Chat with us, powered by LiveChat

Antacids Market (Drug Class - Proton Pump Inhibitor, H2 Antagonist, and Acid Neutralizers; Formulation - Tablet, Liquid, and Powder; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Antacids Market (Drug Class - Proton Pump Inhibitor, H2 Antagonist, and Acid Neutralizers; Formulation - Tablet, Liquid, and Powder; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Report Code: IGR01266 Category: Healthcare & Medical Devices Published: December, 2023

A recent report published by Infinium Global Research on antacids market provides in-depth analysis of segments and sub-segments in the global as well as regional antacids market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional antacids market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global antacids market.

Market Insight:

The global antacids market was valued at USD 5.07 billion in 2022 and is expected to reach USD 7.38 billion in 2030, with a CAGR of 4.11% during the forecast period 2023-2030.

An antacid is a substance that neutralizes stomach acidity and it is used to relieve the body from indigestion and upset stomach. When excessive amounts of acids are produced in the stomach the natural mucous barrier that protects the stomach can damage the esophagus with acid. Combination of aluminum-magnesium antacids are less likely to cause constipation or diarrhea they are only aluminum or only magnesium antacids. They can also be used to relieve the pain of the stomach and ulcers some antacids contain simethicone which reduces gas. Antacids are self-prescribed medicines. Antacids are a combination of various compounds with various salts of calcium, magnesium, and aluminum as active ingredients. The antacids act by neutralizing the acid in the stomach and by inhibiting pepsin, which is a proteolytic enzyme. Each of these cationic salts has a characteristic pharmacological property that determines its clinical use.

The rising prevalence of digestive disorders has become a significant driver for the antacids market. As digestive diseases such as Gastroesophageal Reflux Disease (GERD) and gastritis become more common, there is an increasing demand for antacid medications to alleviate discomfort and manage symptoms. This surge in the number of individuals seeking relief from digestive issues is driving the growth of the antacids market. Further, changing dietary habits has also played a pivotal role in driving market growth. Modern lifestyles often involve hectic routines and unhealthy eating patterns, which contribute to a higher incidence of gastrointestinal problems. As people continue to adopt these dietary habits, the need for effective antacids to combat symptoms like heartburn and indigestion remains robust, further contributing to market growth. However, the prevalence of side effects associated with the consumption of antacids can hinder market growth. Nonetheless, the development of innovative antacid products provides lucrative opportunities for market growth.

Antacids Market Size, Share, Trends, Industry Report | IGR

The antacids market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America is expected to hold a maximum share of the antacids market during the projected period. The region boasts a well-developed and established healthcare system and infrastructure. This advanced healthcare framework ensures that a wide range of medical services, including diagnosis, treatment, and access to pharmaceuticals like antacids, are readily available to the population. This ease of access contributes significantly to the market's growth, as individuals can efficiently seek and obtain relief for their digestive issues. Additionally, another factor contributing to North America's dominance in the antacids market is the region's aging demographic. The United States and Canada, in particular, have seen an increase in their geriatric populations. As individuals age, they become more susceptible to digestive problems such as Gastroesophageal Reflux Disease (GERD) and gastritis. Consequently, the rising number of elderly individuals in North America creates a demand for antacid medications to manage their gastrointestinal symptoms. Moreover, the Asia Pacific region is anticipated to grab a significant share of the market. This is primarily due to, the Asia Pacific region experiencing rapid economic development, leading to an expansion of the middle-class population with increased disposable income. As individuals in this region attain higher levels of income, they have greater access to healthcare services and products. This includes antacids, which are often available as over-the-counter medications. The rising affluence in countries like China, India, and Southeast Asian nations fuels the demand for antacids as people become more health-conscious and seek relief from digestive discomfort. Additionally, the Asia Pacific region is characterized by its large and diverse population, including a growing elderly demographic. These factors are driving the growth of the market in the region.

Report Scope of the Antacids Market:

Report Coverage Details
Market Size in 2022 USD 5.07 Billion
Market Size by 2030 USD 7.38 Billion
Growth Rate from 2023 to 2030 CAGR of 4.11%
Largest Market North America
No. of Pages 255
Market Drivers
  • The rising prevalence of digestive disorders is driving the growth of the market.

  • The changing dietary habits are contributing to the growth of the market.

Market Segmentation By Drug Class, By Formulation, and By Distribution Channel
Regional Scope North America, Europe, Asia Pacific, and RoW

Segment Covered

The report on global antacids market covers segments such as drug class, formulation, and distribution channel. On the basis of drug class, the sub-markets include proton pump inhibitor, H2 antagonist, and acid neutralizers. On the basis of formulation, the sub-markets include tablet, liquid, and powder. On the basis of distribution channel, the sub-markets include hospital pharmacy, retail pharmacy, and online pharmacy.

The report provides the profile of the companies operating in the market such as GSK plc., Bayer AG, Pfizer Inc., Johnson & Johnson Services, Inc., Procter & Gamble, Acme United Corporation, Allegiant Health, Dr. Reddy’s Laboratories Ltd., Reckitt Benckiser Group PLC, and WellSpring Pharmaceutical Corporation.

Report Highlights:

The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the antacids market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Frequently Asked Questions (FAQ's)

The global antacids market was valued at USD 5.07 Billion in 2022.
It is likely to grow at a CAGR of 4.11% during the forecast period 2023-2030.
The global antacids market is estimated to reach USD 7.38 Billion by the end of 2030.
North America is anticipated to exhibit high demand for antacids market during the forecast period.
GSK plc., Bayer AG, Pfizer Inc., Johnson & Johnson Services, Inc., Procter & Gamble, Acme United Corporation, Allegiant Health, Dr. Reddy’s Laboratories Ltd., Reckitt Benckiser Group PLC, and WellSpring Pharmaceutical Corporation.
CHOOSE LICENCE TYPE

Please Choose One of them.

Google translate
© 2024. Infinium Global Research LLP. All Rights Reserved.